<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg"/></p>
<p>SLTE-1009 是一種單克隆抗體，旨在靶向 PACAP 以預防偏頭痛和其他頭痛疾病。圖片來源：Komsan Loonprom / Shutterstock.com。</p>
<p>Slate Medicines 已獲得 1.3 億美元的 A 輪融資，旨在推進抗垂體腺苷酸酰化酶激活多肽（PACAP）偏頭痛療法。</p>
<p>這筆資金與 SLTE-1009 的許可使用相吻合，該抗 PACAP 單克隆抗體是從 DartsBio Pharmaceuticals（廣東）獲得的。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - SL-172154 在骨髓增生異常綜合症中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - SL-172154 在難治性急性髓性白血病中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>該公司由首席執行官兼董事會成員 Gregory Oakes 領導，他在臨牀階段和商業生物製藥組織中擁有超過 30 年的經驗。</p>
<p>Oakes 曾擔任 Raven（RA Capital 的醫療保健部門）的風險合夥人，並在 Celgene、Landos Biopharma、Vifor Pharma 和諾華擔任高管職務。</p>
<p>Neil Buckley 在擔任 Raven 的風險合夥人後加入公司，擔任首席運營官和總裁。臨牀團隊包括首席醫學官 Roger Cady，他是頭痛醫學專家，曾擔任 Alder Biopharmaceuticals 的神經學副總裁。</p>
<p>SLTE-1009 也被稱為 DS009，是一種單克隆抗體，旨在靶向 PACAP 以預防偏頭痛和其他頭痛疾病。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>PACAP 被認為是一個與降鈣素基因相關肽（CGRP）相比具有明顯臨牀驗證的靶點，可能為那些現有療法效果不佳的患者提供益處。</p>
<p>SLTE-1009 採用了半衰期延長技術，允許皮下給藥。Slate Medicines 還在開發另一個管線項目，具體細節尚未披露。</p>
<p>Oakes 表示：“憑藉引人注目的生物學、差異化的產品特徵和強大的投資者支持，Slate Medicines 有望重新定義需要新選擇的患者的偏頭痛預防。”</p>
<p>“我們相信 SLTE-1009 不僅為患者提供了一種新的偏頭痛預防機制，還通過方便的家庭皮下給藥改善了可及性。”</p>
<p>Cady 表示：“PACAP 阻斷代表了一種臨牀驗證的偏頭痛預防方法。對於數百萬對現有標準治療反應不足的患者，我們相信 SLTE-1009 提供了一種新穎的、正交的方法來預防偏頭痛。”</p>
<p>Andrew Levin（RA Capital）、Tim Lohoff（Forbion）和 Cindy Xiong（Foresite Capital）將在此次融資後加入 Slate Medicines 的董事會。</p>

福泰制藥

SLRX

Blueprint醫藥

<p>Slate Medicines 在一輪 A 輪融資中籌集了 1.3 億美元，以推進其抗 PACAP 偏頭痛療法，特別是單克隆抗體 SLTE-1009。這筆資金是在從 DartsBio Pharmaceuticals 獲得 SLTE-1009 的許可後獲得的。該公司旨在提供一種新穎的偏頭痛預防機制，針對對現有治療反應不佳的患者。首席執行官 Gregory Oakes 強調了 SLTE-1009 通過方便的皮下給藥提高患者可及性的潛力。這輪融資還為董事會帶來了來自 RA Capital、Forbion 和 Foresite Capital 的新成員</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg"/></p>
<p>SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders. Credit: Komsan Loonprom / Shutterstock.com.</p>
<div class="lb-trans"><p>SLTE-1009 是一種單克隆抗體，旨在靶向 PACAP 以預防偏頭痛和其他頭痛疾病。圖片來源：Komsan Loonprom / Shutterstock.com。</p>
</div><p>Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.</p>
<div class="lb-trans"><p>Slate Medicines 已獲得 1.3 億美元的 A 輪融資，旨在推進抗垂體腺苷酸酰化酶激活多肽（PACAP）偏頭痛療法。</p>
</div><p>The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong).</p>
<div class="lb-trans"><p>這筆資金與 SLTE-1009 的許可使用相吻合，該抗 PACAP 單克隆抗體是從 DartsBio Pharmaceuticals（廣東）獲得的。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - SL-172154 in Myelodysplastic Syndrome</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - SL-172154 在骨髓增生異常綜合症中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - SL-172154 in Refractory Acute Myeloid Leukemia</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - SL-172154 在難治性急性髓性白血病中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The company is headed by CEO and board director Gregory Oakes, who brings more than 30 years of experience from clinical-stage and commercial biopharma organisations.</p>
<div class="lb-trans"><p>該公司由首席執行官兼董事會成員 Gregory Oakes 領導，他在臨牀階段和商業生物製藥組織中擁有超過 30 年的經驗。</p>
</div><p>Oakes previously worked as a venture partner at Raven, RA Capital’s healthcare arm, and held executive roles at Celgene, Landos Biopharma, Vifor Pharma, and Novartis.</p>
<div class="lb-trans"><p>Oakes 曾擔任 Raven（RA Capital 的醫療保健部門）的風險合夥人，並在 Celgene、Landos Biopharma、Vifor Pharma 和諾華擔任高管職務。</p>
</div><p>Neil Buckley has joined as COO and president after serving as a venture partner at Raven. The clinical team includes chief medical officer Roger Cady, a specialist in headache medicine and former neurology vice-president at Alder Biopharmaceuticals.</p>
<div class="lb-trans"><p>Neil Buckley 在擔任 Raven 的風險合夥人後加入公司，擔任首席運營官和總裁。臨牀團隊包括首席醫學官 Roger Cady，他是頭痛醫學專家，曾擔任 Alder Biopharmaceuticals 的神經學副總裁。</p>
</div><p>Also referred to as DS009, SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders.</p>
<div class="lb-trans"><p>SLTE-1009 也被稱為 DS009，是一種單克隆抗體，旨在靶向 PACAP 以預防偏頭痛和其他頭痛疾病。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>PACAP is considered a distinct clinically validated target compared to calcitonin gene-related peptide (CGRP), possibly offering benefits for those not effectively treated by current therapies.</p>
<div class="lb-trans"><p>PACAP 被認為是一個與降鈣素基因相關肽（CGRP）相比具有明顯臨牀驗證的靶點，可能為那些現有療法效果不佳的患者提供益處。</p>
</div><p>SLTE-1009 incorporates half-life extension technology, allowing for subcutaneous dosing. Slate Medicines is also developing another pipeline project, details of which have not yet been disclosed.</p>
<div class="lb-trans"><p>SLTE-1009 採用了半衰期延長技術，允許皮下給藥。Slate Medicines 還在開發另一個管線項目，具體細節尚未披露。</p>
</div><p>Oakes said: “With compelling biology, a differentiated product profile, and strong investor backing, Slate Medicines is positioned to redefine migraine prevention for patients who need new options.</p>
<div class="lb-trans"><p>Oakes 表示：“憑藉引人注目的生物學、差異化的產品特徵和強大的投資者支持，Slate Medicines 有望重新定義需要新選擇的患者的偏頭痛預防。”</p>
</div><p>“We believe that SLTE-1009 not only offers patients a novel mechanism for migraine prevention but also improved access through convenient at-home subcutaneous dosing.”</p>
<div class="lb-trans"><p>“我們相信 SLTE-1009 不僅為患者提供了一種新的偏頭痛預防機制，還通過方便的家庭皮下給藥改善了可及性。”</p>
</div><p>Cady said: “PACAP blockade represents a clinically validated approach for the prevention of migraine headaches. For the millions of patients with an inadequate response to the existing standard of care, we believe that SLTE-1009 offers a novel, orthogonal approach to preventing migraines.”</p>
<div class="lb-trans"><p>Cady 表示：“PACAP 阻斷代表了一種臨牀驗證的偏頭痛預防方法。對於數百萬對現有標準治療反應不足的患者，我們相信 SLTE-1009 提供了一種新穎的、正交的方法來預防偏頭痛。”</p>
</div><p>Andrew Levin (RA Capital), Tim Lohoff (Forbion), and Cindy Xiong (Foresite Capital) will join Slate Medicines’ Board of Directors following this financing round.</p>
<div class="lb-trans"><p>Andrew Levin（RA Capital）、Tim Lohoff（Forbion）和 Cindy Xiong（Foresite Capital）將在此次融資後加入 Slate Medicines 的董事會。</p>
</div>

Slate Medicines raises $130m in funds to progress anti-PACAP treatments

Pharmaceutical Technology

Salarius Pharmaceuticals

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

美國制藥 ETF - iShares

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

Slate Medicines 籌集 1.3 億美元資金以推進抗 PACAP 治療的進展